Literatuur
- Choueiri et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open-label, phase 3 trial. Lancet Oncology. 2016; 17:917-27
- Choueiri et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2021; 384:829-41
- Choueiri et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncology. 2023 Mar; 24(3):228-238
- Choueiri et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. New England Journal of Medicine. 2024; 390(15):1359-71
- Escudier et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preferences for pazopanib versus sunitinib in patients with metastastic renal cell carcinoma: PISCES study. Journal of Clinical Oncology. 2014; 32(14):1412-18
- Heng et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology 2013; 14(2):141-148
- Motzer et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007; 356(2):115-24
- Motzer et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008; 372:449-56
- Motzer et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine. 2013; 369:772-31
- .Motzer et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine. 2015; 373(19):1803-1913
- Motzer et al. Nivolumab plus ipilimumab versus sunitinib in advance renal-cell carcinoma. New England Journal of Medicine. 2018; 378(14):1277-90
- Motzer et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine. 2021; 384(14):1289-300
- Rini et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019; 380:1116-27
- Yip et al. Outcomes of metastatic chromophobe renal cell carcinoma (chRCC) in the targeted therapy era: results from the international metastatic renal cell cancer database consortium (IMDC). Kidney Cancer. 2021; 41-47
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over niercelcarcinoom.
Richtlijnen
Ga naar de richtlijn Niercelcarcinoom in de FMS richtlijnendatabase.
Ga naar de richtlijn Niercelcarcinoom van VKGN - StOET.